Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.48 |
| ▸ | SCN3A | Q9NY46 | 8/20 | 0.46 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.44 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.44 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.44 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.44 |
| ▸ | SCN1A | P35498 | 1/20 | 0.43 |
| ▸ | SCN4A | P35499 | 1/20 | 0.43 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.43 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.43 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.43 |
| ▸ | HPD | P32754 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12973299 | 0.89 | MAOB (0.47) | MAOBKCNH2SCN3APARP15PARP10 | |
| SCHEMBL22534101 | 0.87 | MAOB (0.49) | MAOBKCNH2SCN3APARP15PARP10 | |
| SCHEMBL2712980 | 0.87 | MAOB (0.49) | MAOBKCNH2SCN3APARP15PARP10 | |
| SCHEMBL2837133 | 0.85 | KCNH2 (0.53) | MAOBKCNH2SCN3APARP15PARP10 | |
| SCHEMBL13320301 | 0.77 | MAOB (0.54) | MAOBKCNH2SCN3APARP15PARP10 | |
| SCHEMBL22534110 | 0.77 | SCN3A (0.54) | MAOBKCNH2SCN3APARP15PARP10 | |
| SCHEMBL22534112 | 0.77 | SCN3A (0.54) | MAOBKCNH2SCN3APARP15PARP10 | |
| SCHEMBL2836385 | 0.76 | KCNH2 (0.51) | KCNH2SCN3APARP15PARP10 | |
| SCHEMBL4515003 | 0.76 | KMO (0.40) | — | |
| SCHEMBL4515010 | 0.76 | KMO (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855218-B2 | (5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide; depression or a mood disorder ; modulation of use-dependent voltage-gated sodium channels | Convergence Pharmaceuticals Limited (GB) | 2010-12-21 | — | — | US | disclosed |
| EP-1943216-B1 | PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | GLAXO GROUP LTD (GB) | 2010-06-30 | — | — | EP | disclosed |
| US-20080306122-A1 | Novel Compounds | Convergence Pharmaceuticals Limited (GB) | 2008-12-11 | — | — | US | disclosed |
| EP-1943216-A1 | PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | GLAXO GROUP LIMITED (GB) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007042250-A1 | PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | GLAXO GROUP LIMITED (GB) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306122-A1 | Novel Compounds | CYP11B1, CYP11B2, CYP46A1 | MAOB 1619/4885KCNH2 3313/4885SCN3A 2352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.